ClinicalTrials.gg
CompletedNCT03375164Updated Nov 14, 2024Results posted

A Gene Transfer Therapy Study to Evaluate the Safety of Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD)

A Phase 1/2 interventional study of delandistrogene moxeparvovec in Duchenne Muscular Dystrophy, sponsored by Sarepta Therapeutics, Inc.. Completed at 1 site in United States. Open to male participants aged 3 Months to 7 Years. Per ClinicalTrials.gov, last updated 2024-11-14.

Sponsored by Sarepta Therapeutics, Inc. · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
4
Allocation
Non-randomized
Ages
3 Months to 7 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. — 5 open to participants now, 6 under way, 2 of them phase 3. Muscular Dystrophy, Duchenne · Sarepta Therapeutics, Inc..

Enrollment
24th of 25
4 · median 24
Started
2018
with 4 others
Phase 1/2
5 of 27
none open now
Registered
11th of 27
by date

Among the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., this one is the 24th largest by enrollment of the 25 interventional ones that give a count, is one of 5 that started in 2018, is one of 5 in phase 1/2, and was the 11th registered.

Muscular Dystrophy, Duchenne

482 studies on the registry are indexed under Muscular Dystrophy, Duchenne; 107 are open to participants now.

Browse Muscular Dystrophy, Duchenne studies →

Open to participants now

5 of the 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc. are open now, in 9 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 65 Muscular Dystrophy, Duchenne studies recruiting now, 30 (46%) set no upper age limit and 33 (51%) stop at 75 or younger; 58 take children under 18; 11 take healthy volunteers.

This study: 3 Months to 7 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Muscular Dystrophy, Duchenne by Sarepta Therapeutics, Inc., or all of them as a file.
02

Study summary

This study was an open-label single-dose gene transfer therapy study evaluating the safety of delandistrogene moxeparvovec intravenous (IV) administration in boys with DMD. This study was originally designed to consist of 12 patients across 2 Cohorts. Cohort A would have included participants ages 3 months to 3 years, and Cohort B included participants ages 4 to 7 years old. No participants were enrolled in Cohort A.

03

Conditions studied

  • Duchenne Muscular Dystrophy

Keywords

  • Duchenne
  • Gene Therapy
  • DMD
  • Dystrophin
  • Pediatric
  • Gene-Delivery
  • Gene Transfer Therapy
04

Who can participate

Ages eligible
3 Months to 7 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Cohort A participants: 3 months to 3 years of age, inclusive
  • Cohort B participants: 4 to 7 years of age, inclusive
  • Definitive diagnosis of DMD based on documented clinical findings and prior genetic testing.
  • Ability to cooperate with motor assessment testing.
  • Cohort A participants: No previous treatment with .
  • Cohort B participants: Stable dose equivalent of oral corticosteroids for at least 12 weeks prior to screening and the dose is expected to remain constant (except for potential modifications to accommodate changes in weight) throughout the first year of the study.
  • Cohorts A \& B: A frameshift mutation contained between exons 18 and 58 (inclusive).

Exclusion criteria

Exclusion Criteria:

  • Exposure to gene therapy, medication, or any treatment designed to increase dystrophin expression within protocol specified time limits.
  • Abnormality in protocol-specified diagnostic evaluations or laboratory tests.
  • Presence of any other illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer.

Other inclusion or exclusion criteria could apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
4 participants (actual)

Study arms

  • Experimental
    Cohort A: Delandistrogene Moxeparvovec

    Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.

    Genetic: delandistrogene moxeparvovec

  • Experimental
    Cohort B: Delandistrogene Moxeparvovec

    Participants will receive a Single IV infusion of delandistrogene moxeparvovec on Day 1.

    Genetic: delandistrogene moxeparvovec

Interventions

  • Geneticdelandistrogene moxeparvovec

    Single IV infusion of delandistrogene moxeparvovec.

    Also known as: SRP-9001, delandistrogene moxeparvovec-rokl, ELEVIDYS

06

What researchers measure

Primary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurs during or after administration of a study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

    Time frame: Up to 5 years

Secondary outcomes

  1. Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Western Blot

    Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin protein levels in these muscle biopsy samples was determined by Western blot. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.

    Time frame: Baseline, Day 90

  2. Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Immunofluorescence (IF) Fiber Intensity

    Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF fiber intensity indicates increased delandistrogene moxeparvovec dystrophin expression.

    Time frame: Baseline, Day 90

  3. Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by IF Percent Dystrophin Positive Fibers (PDPF)

    Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates increased delandistrogene moxeparvovec dystrophin expression.

    Time frame: Baseline, Day 90

  4. Change From Baseline at Year 5 in the 100 Meter Timed Test

    This assessment measures the time needed to move 100 meters and served as the primary motor outcome measure for this study. A decrease in the time needed to move 100 meters indicates increased motor function.

    Time frame: Baseline, Year 5

07

Results

Posted May 23, 2024

Participant flow

Participant flow — Overall Study
MilestoneDelandistrogene Moxeparvovec
Started4
Received at least 1 dose of study drug4
Completed4
Not completed0

Outcome measures

PrimaryNumber of Participants With Adverse Events (AEs)

An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the study drug. An AE can, therefore, be any unfavorable and unintended symptom, sign, disease, condition, or test abnormality that occurs during or after administration of a study drug, whether or not considered related to the study drug. A summary of serious and all other non-serious adverse events regardless of causality is located in the Reported Adverse Events module.

Time frame:
Up to 5 years
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs)
ParticipantsDelandistrogene Moxeparvovec
Number of Participants With Adverse Events (AEs)4
SecondaryChange From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Western Blot

Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin protein levels in these muscle biopsy samples was determined by Western blot. An increase in protein expression indicates production of the delandistrogene moxeparvovec dystrophin protein.

Time frame:
Baseline, Day 90
Reported as:
Mean · percent control
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Western Blot
percent controlDelandistrogene Moxeparvovec
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Western Blot70.52 ± 76.10
SecondaryChange From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Immunofluorescence (IF) Fiber Intensity

Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined using IF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF fiber intensity indicates increased delandistrogene moxeparvovec dystrophin expression.

Time frame:
Baseline, Day 90
Reported as:
Mean · percent fluorescent expression
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Immunofluorescence (IF) Fiber Intensity
percent fluorescent expressionDelandistrogene Moxeparvovec
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by Immunofluorescence (IF) Fiber Intensity93.59 ± 43.86
SecondaryChange From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by IF Percent Dystrophin Positive Fibers (PDPF)

Baseline muscle biopsies with ultrasound guidance were performed pre-treatment and post-treatment (Day 90) on all participants. The change from baseline in delandistrogene moxeparvovec dystrophin expression in these muscle biopsy samples was determined by IF PDPF. Automated software was used to quantify the intensity of dystrophin expression post-treatment compared to pre-treatment (Percent Normal). The number of muscle fibers expressing micro-dystrophin was quantified by independent trained evaluators. An increase in IF PDPF indicates increased delandistrogene moxeparvovec dystrophin expression.

Time frame:
Baseline, Day 90
Reported as:
Mean · percent dystrophin positive fibers
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by IF Percent Dystrophin Positive Fibers (PDPF)
percent dystrophin positive fibersDelandistrogene Moxeparvovec
Change From Baseline at Day 90 in Delandistrogene Moxeparvovec Dystrophin Expression as Measured by IF Percent Dystrophin Positive Fibers (PDPF)81.18 ± 10.19
SecondaryChange From Baseline at Year 5 in the 100 Meter Timed Test

This assessment measures the time needed to move 100 meters and served as the primary motor outcome measure for this study. A decrease in the time needed to move 100 meters indicates increased motor function.

Time frame:
Baseline, Year 5
Reported as:
Mean · second
Change From Baseline at Year 5 in the 100 Meter Timed Test
secondDelandistrogene Moxeparvovec
Change From Baseline at Year 5 in the 100 Meter Timed Test-4.02 ± 4.64

Adverse events

Collected over Up to 5 years. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Delandistrogene Moxeparvovec0/4 (0%)0/4 (0%)4/4 (100%)
Most frequent other events
Showing 10 of 34
Most frequent other events
EventDelandistrogene Moxeparvovec
Upper respiratory tract infectionInfections and infestations4/4
VomitingGastrointestinal disorders4/4
Hepatic enzyme increasedInvestigations3/4
Gastrooesophageal reflux diseaseGastrointestinal disorders2/4
FatigueGeneral disorders2/4
COVID-19Infections and infestations2/4
Procedural painInjury, poisoning and procedural complications2/4
Decreased appetiteMetabolism and nutrition disorders2/4
CoughRespiratory, thoracic and mediastinal disorders2/4
Abdominal discomfortGastrointestinal disorders1/4

Baseline characteristics

Full Analysis Set: all participants who received study treatment.

Age, Continuous
Age, Continuous(years)Delandistrogene Moxeparvovec
Mean5.14 ± 0.91
Age, Customized
Age, Customized(Participants)Delandistrogene Moxeparvovec
In utero0
Preterm newborn infants (gestational age < 37 wks)0
Newborns (0-27 days)0
Infants and toddlers (28 days-23 months)0
Children (2-11 years)4
Adolescents (12-17 years)0
Adults (18-64 years)0
From 65-84 years0
85 years and over0
Sex: Female, Male
Sex: Female, Male(Participants)Delandistrogene Moxeparvovec
Female0
Male4
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Delandistrogene Moxeparvovec
Hispanic or Latino0
Not Hispanic or Latino4
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Delandistrogene Moxeparvovec
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White3
More than one race0
Unknown or Not Reported1
08

Study locations

1 site
  • Nationwide Children's Hospital
    Columbus, Ohio 43205, United States
09

References and documents

Publications

  • Mendell JR, Sahenk Z, Lehman K, Nease C, Lowes LP, Miller NF, Iammarino MA, Alfano LN, Nicholl A, Al-Zaidy S, Lewis S, Church K, Shell R, Cripe LH, Potter RA, Griffin DA, Pozsgai E, Dugar A, Hogan M, Rodino-Klapac LR. Assessment of Systemic Delivery of rAAVrh74.MHCK7.micro-dystrophin in Children With Duchenne Muscular Dystrophy: A Nonrandomized Controlled Trial. JAMA Neurol. 2020 Sep 1;77(9):1122-1131. doi: 10.1001/jamaneurol.2020.1484. PubMed 32539076 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2018 to primary completion in Apr 2023, 63 months.

Results were first posted in May 2024, 1 year after primary completion.

Of 23 phase 1/2 interventional studies under Muscular Dystrophy, Duchenne, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's 63 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2017
First posted
Dec 15, 2017
StartActual
Jan 4, 2018
Primary completionActual
Apr 25, 2023
CompletionActual
Apr 25, 2023
Results first posted
May 23, 2024
Last update
Nov 14, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03375164
Responsible party
Sponsor
First posted
Dec 15, 2017
Start date
Jan 4, 2018
Primary completion
Apr 25, 2023
Completion
Apr 25, 2023
Results posted
May 23, 2024
Last update
Nov 14, 2024

Study contacts

Medical Director
study director · Sarepta Therapeutics, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion